BEIJING, February 4, 2016 – Pharmaron, a fully integrated contract research organization (CRO) offering laboratory and manufacturing services for pharmaceutical and biotech research and development, today announced that it acquired Quotient Bioresearch (Quotient). Quotient, a UK-based CRO with more than 200 employees, focuses on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient's previous acquisition of GE Amersham's radiosynthesis business.
Integrated with Pharmaron's broader technology platforms in chemistry, biology, DMPK, pharmacology, safety assessment, chemical and pharmaceutical development, this acquisition strengthens the company's service portfolio, allowing it to provide more comprehensive and integrated services. The addition of the radiochemistry capabilities creates a global leading chemistry platform with a full spectrum of services. Further, the combined entity will generate greater market access in Asia, Europe and the United States.
"We are very pleased to have Quotient Bioresearch join the Pharmaron team." said Dr. Boliang Lou, Chairman and Chief Executive Officer of Pharmaron. "This acquisition is part of our long-term strategy to grow our services and broaden our technical and geographic footprint to better serve clients throughout the world. Combining these two companies gives Pharmaron industry-leading custom radiosynthesis capabilities, and further consolidates our leading position in the field of discovery, pre-clinical and clinical DMPK. This move will help accelerate the discovery and development of novel drugs for our customers with Pharmaron's comprehensive and integrated drug research and development engine."
Stephen Lewinton, Managing Director of Quotient, said, "Quotient is focused on radiosynthesis and regulatory DMPK, particularly human clinical metabolism while Pharmaron has premier expertise in drug R&D services including discovery and pre-clinical safety and early phase DMPK. We are excited to become part of Pharmaron's integrated drug research and development platform."
Teneo Capital served as financial advisor to Pharmaron in the transaction and O'Melveny & Meyers LLP served as Pharmaron's legal advisor.
Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2003, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology and safety assessment to chemical & pharmaceutical development. With over 3,000 employees and operations in China and the U.S., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, please visit:
Quotient Bioresearch is a leading UK CRO based in Cardiff and Northampton, providing Radiochemistry, Drug Metabolism and E-fate solutions tailored, integrated and delivered to pharmaceutical, biotechnology, agrochemical and chemical sponsors worldwide, using state-of-the-art technologies underpinned by unparalleled scientific, chemical and biological expertise. The Cardiff site derived from the acquisition of Amersham custom radiolabeling business from GE Healthcare. Amersham, the premier radiosynthesis laboratories in the world, was founded in 1940. The Northampton site derived from the acquisition of BioDynamics, a specialist DMPK CRO founded in early 90s. For more information, please visit:
Ashok Tehim, Ph.D.
Senior Vice President of Strategy
- See more at: http://www.pharmaron.com/news/pharmaron-acquires-quotient-bioresearch/#sthash.sci19ecT.dpuf